Key result
Among patients with venous thromboembolism treated with vitamin K antagonists, the mean time in therapeutic range was suboptimal at 41.2%, with 74.3% of patients having a TTR below 65%.
Why the study?
Patients with VTE frequently require VKAs, but the quality of anticoagulation using time in therapeutic range, associated predictors of poor control, and outcomes required evaluation.
Observational (n=171)
No
Vitamin K antagonist therapy for VTE in Morocco is associated with poor anticoagulation control (mean TTR 41.2%), highlighting the potential need for wider use of direct oral anticoagulants in resource-constrained settings.
Background: Patients with venous thromboembolism (VTE) frequently require vitamin K antagonists (VKAs) to treat and prevent recurrent events. Aims: We performed a study to assess the quality of anticoagulation in patients with VTE treated with VKAs using time in therapeutic range (TTR), to identify associated factors with predictors of poor control and outcomes in VTE patients. Methods: We performed an observational, retrospective study that included VTE patients treated with VKA. The primary outcome was the TTR calculated according to the Rosendaal algorithm. Results: 171 VKA-treated patients were evaluated (53.2% men). The average age of our patients at diagnosis was 49.8 + 16.6 years [17-92]. VTE's most common location was the lower limbs, with 91.8 % cases, proximal in 83.6%. Patients were followed for a mean period of 178 days. The mean TTR was 41.2% (SD 32.9%), and 74.3% of the patients had a mean TTR < 65%. The rates of major bleeds and thromboembolic events were 0.5% and 2.2%, respectively. After multivariate statistical analysis, age older than 65 and surgery provoked VTE were associated with better TTR. Conclusions: These results are informative and may help identify patients who require closer monitoring or innovative strategies to optimize oral anticoagulant therapy outcomes.
No takes yet. Share an insight, caveat, or question.
Mezalek et al. (2026) conducted an observational in Venous thromboembolism (n=171). Vitamin K antagonists was evaluated on Mean time in therapeutic range (TTR) according to the Rosendaal algorithm. Among patients with venous thromboembolism treated with vitamin K antagonists, the mean time in therapeutic range was suboptimal at 41.2%, with 74.3% of patients having a TTR below 65%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: